Citius Pharmaceuticals’ Lymphir is a reformulated version of denileukin diftitox—an FDA-approved cancer therapy—and the only treatment for cutaneous T-cell lymphoma that targets the IL-2 receptor located on malignant T cells and Tregs.
Citius Pharmaceuticals’ Lymphir is a reformulated version of denileukin diftitox—an FDA-approved cancer therapy—and the only treatment for cutaneous T-cell lymphoma that targets the IL-2 receptor located on malignant T cells and Tregs.